IgA Nephropathy clinical trials at UC Health
3 research studies open to eligible people
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
open to eligible people ages 18-65
The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). These patients are at high risk for progression of kidney disease, which can result in end-stage renal failure.
at UCLA UCSF
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
open to eligible people ages 18 years and up
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
at UCLA
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the safety and efficacy of OMS721 in patients with IgA nephropathy. The study will assess proteinuria by 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment.
at UCLA
Last updated: